A randomised trial of Conventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases

CORE is a phase II/III, multicentre, non-blinded, randomised controlled trial in patients with breast, prostate or non-small cell lung cancer (NSCLC) primary cancer to evaluate if the addition of stereotactic body radiotherapy (SBRT) to standard therapy improves progression-free survival outcomes in patients with extra-cranial metastases that have spread from either their lung, breast and/or prostate cancer.

Primary Sponsor

The Institute of Cancer Research (UK)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Participating Centres

Final Accrual

235

Current Accrual

Closing Date of Accrual

February 2019

Trial Chairperson

A/Prof David Pryor, Princess Alexandra Hospital, QLD
A/Prof Farshad Foroudi, Austin Health - Olivia Newton John Cancer and Wellness Centre, VIC

Trial Contact

CORE@trog.com.au

Related Post

August 2, 2022

Celebrating and bringing radiation medicine research to the forefront at our 2022 ASM

After a hiatus from in-person events due to COVID-19

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a